Nasdaq
$0.9300▼ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $14.5MShares out 15.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.29After-hours26.09.30 05:154Ownership#●●●#●●●
FIREFLY NEUROSCIENCE, INC.
Director Stella Vnook of Firefly Neuroscience, Inc. reported a change in beneficial ownership of securities effective September 25, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$0.9300-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29After-hours26.09.30 05:154Ownership
FIREFLY NEUROSCIENCE, INC.
Brian M. Posner, an insider at Firefly Neuroscience, Inc., filed a Form 4 on September 29, 2026, reporting changes in beneficial ownership of securities as of September 25, 2026. This filing serves as an official record of the insider's equity transaction.…more
$0.9300-0.03%vs prev closeView filingShare - 9.29After-hours26.09.30 05:154Ownership
FIREFLY NEUROSCIENCE, INC.
Insider Arun Swarup Menawat of Firefly Neuroscience reported a change in beneficial ownership of securities as of September 25, 2026. This filing is a Form 4 statement detailing the executive's equity position adjustments.…more
$0.9300-0.03%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.25Regular26.09.26 02:53#●●●#●●●#●●●
Firefly Neuroscience Partners with NeuroSigma for Pediatric ADHD Care
Firefly Neuroscience has partnered with NeuroSigma to integrate its AI-powered diagnostic platform with the Monarch eTNS non-drug ADHD treatment system. This collaboration aims to provide clinicians with objective brain function insights and alternative treatment options for pediatric ADHD patients.…more
$0.9300-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.25Pre-market26.09.25 20:47
●●●●●●●● ●●●●● ●●●●●●
Firefly Neuroscience is partnering with NeuroSigma to expand the reach of the FDA-cleared Monarch eTNS system for pediatric ADHD using its AI-powered Evoke platform. This collaboration aims to provide clinicians with objective brain function data and non-medication treatment options for patients.…more
$0.9300-0.03%vs prev closeShareBenzinga - 9.25Pre-market26.09.25 20:45
●●●●●●●● ●●●●● ●●●●●●
Firefly is partnering with NeuroSigma to expand access to an FDA-cleared, non-drug ADHD treatment through its existing clinical network. This collaboration is a strategic partnership without immediate financial impact, warranting a neutral outlook.…more
$0.9300-0.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report